Germany's Federal Joint Committee (G-BA) has issued its final benefit assessment report for Pixuvri (pixantrone), which is indicated as a monotherapy for the treatment of adult patients with aggressive B-cell non-Hodgkin lymphoma who have failed two or three prior lines of therapy. The G-BA has found that an additional benefit could not be determined for Pixuvri versus the comparator therapies assigned by G-BA.  For more details, go to http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=irol-newsArticle&ID=1821854&highlight=